Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Up 5.5% – What’s Next?

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock price rose 5.5% during mid-day trading on Friday . The stock traded as high as $7.52 and last traded at $7.52. Approximately 116,986 shares traded hands during trading, a decline of 51% from the average daily volume of 239,849 shares. The stock had previously closed at $7.13.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Citigroup upped their price objective on Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $21.13.

Telix Pharmaceuticals Stock Performance

The stock’s 50-day moving average price is $7.30 and its 200 day moving average price is $8.95. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $414.02 million during the quarter, compared to analysts’ expectations of $421.50 million. Sell-side analysts anticipate that Telix Pharmaceuticals Limited will post 0.24 earnings per share for the current year.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Rhumbline Advisers raised its holdings in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares in the last quarter. XTX Topco Ltd bought a new position in Telix Pharmaceuticals during the 4th quarter worth about $89,000. OLD Mission Capital LLC purchased a new position in Telix Pharmaceuticals during the 4th quarter valued at about $111,000. Vident Advisory LLC bought a new stake in shares of Telix Pharmaceuticals in the 4th quarter valued at about $204,000. Finally, IHT Wealth Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.